COMPARATIVE ACTIVITY OF SELECTED ANTIVIRAL COMPOUNDS AGAINST CLINICAL ISOLATES OF HUMAN CYTOMEGALOVIRUS

被引：63

作者：

ANDREI, G ^{[1
]}

SNOECK, R ^{[1
]}

SCHOLS, D ^{[1
]}

GOUBAU, P ^{[1
]}

DESMYTER, J ^{[1
]}

DECLERCQ, E ^{[1
]}

机构：

[1] CATHOLIC UNIV LEUVEN, ACAD HOSP, B-3000 LOUVAIN, BELGIUM

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 1991年 / 10卷 / 12期

关键词：

D O I：

10.1007/BF01984924

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Seventeen fresh clinical isolates of human cytomegalovirus (HCMV) were examined for their in vitro susceptibility to different potential anti-HCMV drugs, including a series of acyclic nucleoside phosphonate analogues as well as the reference compounds ganciclovir, foscarnet and acyclovir. Three sulfated polysaccharides (heparin, dextran sulfate and pentosan polysulfate) known for their ability to inhibit adsorption of enveloped viruses to the cells were also included in these comparative tests. Of the reference compounds, ganciclovir was the most potent. However, it was about five-fold less potent than the phosphonate derivative (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and its cyclic form (cHPMPC). All test compounds, including the sulfated polysaccharides, were as active against the clinical isolates as they were against the laboratory strains of HCMV. Furthermore, the choice of the cell line (HEL or MRC-5) did not influence the anti-HCMV activity of the compounds.

引用

页码：1026 / 1033

页数：8